Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study
- PMID: 20156410
- PMCID: PMC3109728
- DOI: 10.4088/JCP.07m03890yel
Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study
Abstract
Objective: Most previous studies of the incidence of tardive dyskinesia with atypical antipsychotics compared with conventional antipsychotics have not had tardive dyskinesia as their primary focus. The current study aimed to compare the incidence of tardive dyskinesia with atypical vs conventional antipsychotics using methods similar to those from a previous prospective cohort study at our site in the 1980s.
Method: Three hundred fifty-two initially tardive dyskinesia-free psychiatric outpatients (diagnosed at baseline using the Structured Clinical Interview for DSM-IV) were examined for a new diagnosis of tardive dyskinesia (using the Abnormal Involuntary Movement Scale and Glazer-Morgenstern criteria) every 6 months for up to 4 years at a community mental health center. At baseline, subjects were receiving conventional antipsychotics only (23%), atypicals only (64%), or both (14%). Only 26 subjects had never received conventional antipsychotics. Baseline evaluations were conducted from November 2000 through May 2003. Follow-ups were conducted through February 2005.
Results: Compared with subjects treated with conventional antipsychotics alone since the previous visit, the adjusted tardive dyskinesia incidence rate-ratio for subjects treated with atypical antipsychotics alone was 0.68 (95% CI, 0.29-1.64). The incidence and prevalence of tardive dyskinesia was similar to previous findings at this site in the 1980s.
Conclusions: The incidence of tardive dyskinesia with recent exposure to atypical antipsychotics alone was more similar to that for conventional antipsychotics than in most previous studies. Despite high penetration of atypical antipsychotics into clinical practice, the incidence and prevalence of tardive dyskinesia appeared relatively unchanged since the 1980s. Clinicians should continue to monitor for tardive dyskinesia, and researchers should continue to pursue efforts to treat or prevent it.
Copyright 2010 Physicians Postgraduate Press, Inc.
Conflict of interest statement
Declaration of Interest
Dr. Woods acknowledges receipt of investigator-initiated grant support from Bristol Myers-Squibb, Eli Lilly, Janssen, and UCB Pharma and advisory board honoraria from Otsuka and Schering-Plough. Dr. Glazer acknowledges receipt of consultant fees from AstraZeneca, Eli Lilly, and Pfizer and speakers’ bureau honoraria from Eli Lilly.
Similar articles
-
Effects of antipsychotic treatment on tardive dyskinesia: a 6-month evaluation of patients from the European Schizophrenia Outpatient Health Outcomes (SOHO) Study.J Clin Psychiatry. 2005 Sep;66(9):1130-3. J Clin Psychiatry. 2005. PMID: 16187770
-
Incidence of tardive dyskinesia with typical versus atypical antipsychotics in very high risk patients.Biol Psychiatry. 2003 Jun 15;53(12):1142-5. doi: 10.1016/s0006-3223(03)00170-7. Biol Psychiatry. 2003. PMID: 12814866
-
Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study.Arch Gen Psychiatry. 1993 Sep;50(9):723-33. doi: 10.1001/archpsyc.1993.01820210057007. Arch Gen Psychiatry. 1993. PMID: 8102845
-
Tardive dyskinesia rates with atypical antipsychotics in adults: prevalence and incidence.J Clin Psychiatry. 2004;65 Suppl 9:16-20. J Clin Psychiatry. 2004. PMID: 15189107 Review.
-
Tardive dyskinesia rates with atypical antipsychotics in older adults.J Clin Psychiatry. 2004;65 Suppl 9:21-4. J Clin Psychiatry. 2004. PMID: 15189108 Review.
Cited by
-
New and emerging treatments for symptomatic tardive dyskinesia.Drug Des Devel Ther. 2013 Nov 6;7:1329-40. doi: 10.2147/DDDT.S32328. eCollection 2013. Drug Des Devel Ther. 2013. PMID: 24235816 Free PMC article. Review.
-
Recognition and Treatment of Tardive Dyskinesia in Individuals with Intellectual Disability.Case Rep Psychiatry. 2020 Dec 11;2020:8886980. doi: 10.1155/2020/8886980. eCollection 2020. Case Rep Psychiatry. 2020. PMID: 33414976 Free PMC article.
-
Relevance of animal models to human tardive dyskinesia.Behav Brain Funct. 2012 Mar 9;8:12. doi: 10.1186/1744-9081-8-12. Behav Brain Funct. 2012. PMID: 22404856 Free PMC article. Review.
-
Alteration of Cytokines Levels in the Striatum of Rats: Possible Participation in Vacuous Chewing Movements Induced by Antipsycotics.Neurochem Res. 2016 Sep;41(9):2481-9. doi: 10.1007/s11064-016-1961-6. Epub 2016 May 26. Neurochem Res. 2016. PMID: 27230882
-
Incidence of tardive dyskinesia with risperidone or olanzapine in the elderly: results from a 2-year, prospective study in antipsychotic-naïve patients.Neuropsychopharmacology. 2011 Jul;36(8):1738-46. doi: 10.1038/npp.2011.55. Epub 2011 Apr 20. Neuropsychopharmacology. 2011. PMID: 21508932 Free PMC article.
References
-
- Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: A systematic review of 1-year studies. Am J Psychiatry. 2004;161:414–425. - PubMed
-
- Woods SW. Olanzapine and tardive dyskinesia. Br J Psychiatry. 1999;175:391–392. - PubMed
-
- Morgenstern H, Glazer WM, Gibowski LD, et al. Predictors of tardive dyskinesia: Results of a cross sectional study in an outpatient population. J Chron Dis. 1987;40:319–327. - PubMed
-
- Morgenstern H, Glazer WM. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study. Arch Gen Psychiatry. 1993;50:723–733. - PubMed
-
- Branch PR. Abnormal involuntary movement scale (AIMS) Early Clin Drug Eval Unit Intercom. 1975;4:3–6.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical